2025 Speakers

Rand Sutherland, MD is the Chief Executive Officer of Upstream Bio, a clinical-stage company developing verekitug, a novel antibody antagonist of the TSLP receptor, for severe airway diseases. Dr. Sutherland has focused his career on improving care for patients with pulmonary and rare diseases, and he brings more than 25 years of business, R&D and clinical experience to his role. Prior to joining Upstream Bio, Dr. Sutherland was CEO of Seeker Biologics, a private biotechnology company developing a novel class of cell-target biologics, and before that was President of the mRNA platform company Translate Bio, prior to its acquisition by Sanofi. Previously, Dr. Sutherland served in various research and development and medical affairs roles at Sanofi, working to develop and launch innovative medicines in immunology and rare diseases, including Dupixent®, Nexviazyme®, Xenpozyme®, Altuviio® and Enjaymo®. He also serves as an independent director of Krystal Biotech and Vanqua Bio and was previously a director of Allakos. Before joining industry, Dr. Sutherland was Professor of Medicine at the University of Colorado and Chief of Pulmonary and Critical Care Medicine at National Jewish Health in Denver. He holds a B.A. from Oberlin College, an M.P.H. from the Harvard School of Public Health, and an M.D. from the University of Chicago. He trained in Internal Medicine at UCSF, followed by a fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.